Glassman Robert sold $332K of PHVS
Glassman Robert sold 8,667 shares of Pharvaris N.V. (PHVS) at $38.27 ($0.33M total) on 2026-09-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director's sale may be viewed as a bearish cue, but the size is modest.
Market read
New insider sale adds modest negative sentiment for PHVS.
What to watch
The 10b5‑1 plan pre‑arranged nature reduces interpretive weight.
Background
Form 4 filings provide the first public disclosure of insider transactions.
Ticker impact
Director Robert Glassman sold 8,667 shares for $331,716 via a 10b5‑1 plan, reducing his stake to 10,500 shares.
Modest short‑term downside pressure, likely <2% move.
A $332K sale by a director is material for a micro‑cap biotech, but the amount is modest relative to market cap.
Market effects
May raise scrutiny on insider activity within biotech sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Insider sale could be routine liquidity need, not a negative signal.
Key entities
- CompanyPharvaris N.V.
Biotech firm listed on Nasdaq under ticker PHVS.
- DirectorRobert Glassman
Insider who executed the sale.
